Literature DB >> 19819970

Global disturbances in autonomic function yield cardiovascular instability and hypertension in the chromogranin a null mouse.

Jiaur R Gayen1, Yusu Gu, Daniel T O'Connor, Sushil K Mahata.   

Abstract

We reported previously that chromogranin A (Chga) knockout (KO) mice are hypertensive and hyperadrenergic. Here we sought to determine the basis of such alterations by probing physiological, biochemical, and pharmacological responses to perturbations of the autonomic nervous system. In the conscious state, KO mice had substantially elevated basal high blood pressure (BP) and heart rate (HR); immobilization stress caused increments in systolic BP and HR in both wild-type (WT) and KO mice, with higher maxima but blunted increments in the KO state. Catestatin (CST; CHGA(352-372)) selectively diminished stress-induced increments in BP and HR in KO mice, implicating CST as an antihypertensive peptide, even in stressful conditions. Heightened plasma catecholamines in KO mice returned to WT level after CST. Stress caused further increments in catecholamines in WT mice but no change in KO mice. KO mice displayed diminished baroreflex sensitivity in response to either phenylephrine or sodium nitroprusside, accounting for exaggerated pressor and depressor responses to these compounds; baroreceptor function was normalized by CST. To probe the relative roles of endogenous/basal sympathetic vs. parasympathetic tone in control of BP and HR, we used the muscarinic-cholinergic antagonist atropine or the beta-adrenergic antagonist propranolol; HR and BP responses to each antagonist were exaggerated in KO animals. We conclude that ablation of Chga expression results in global disturbances in autonomic function, both sympathetic and parasympathetic, that can be abrogated (or rescued), at least in part, by replacement of CST. The results point to mechanisms whereby CHGA and its CST fragment act to control cardiovascular homeostasis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19819970      PMCID: PMC2775982          DOI: 10.1210/en.2009-0429

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  51 in total

1.  The normal range and determinants of the intrinsic heart rate in man.

Authors:  T Opthof
Journal:  Cardiovasc Res       Date:  2000-01-01       Impact factor: 10.787

2.  Primary structure and function of the catecholamine release inhibitory peptide catestatin (chromogranin A(344-364)): identification of amino acid residues crucial for activity.

Authors:  S K Mahata; M Mahata; A R Wakade; D T O'Connor
Journal:  Mol Endocrinol       Date:  2000-10

3.  Exaggerated adrenomedullary response to immobilization in mice with targeted disruption of the serotonin transporter gene.

Authors:  Olga A Tjurmina; Ines Armando; Juan M Saavedra; David S Goldstein; Dennis L Murphy
Journal:  Endocrinology       Date:  2002-12       Impact factor: 4.736

Review 4.  The chromogranin-secretogranin family.

Authors:  Laurent Taupenot; Kimberly L Harper; Daniel T O'Connor
Journal:  N Engl J Med       Date:  2003-03-20       Impact factor: 91.245

5.  Restraint stress : differential cardiovascular responses in Wistar-Kyoto and spontaneously hypertensive rats.

Authors:  S J McDougall; J R Paull; R E Widdop; A J Lawrence
Journal:  Hypertension       Date:  2000-01       Impact factor: 10.190

6.  Cardiovascular neural reflexes in L-NAME-induced hypertension in mice.

Authors:  V A Peotta; E C Vasquez; S S Meyrelles
Journal:  Hypertension       Date:  2001-09       Impact factor: 10.190

7.  Effect of immobilization stress on brain polyamine levels in spontaneously hypertensive and Wistar-Kyoto rats.

Authors:  Hyung Seok Sohn; Young Nam Park; Seong Ryong Lee
Journal:  Brain Res Bull       Date:  2002-03-15       Impact factor: 4.077

8.  Autonomic cardiovascular control in conscious mice.

Authors:  A Just; J Faulhaber; H Ehmke
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2000-12       Impact factor: 3.619

9.  Early decline in the catecholamine release-inhibitory peptide catestatin in humans at genetic risk of hypertension.

Authors:  Daniel T O'Connor; Mala T Kailasam; Brian P Kennedy; Michael G Ziegler; Noboru Yanaihara; Robert J Parmer
Journal:  J Hypertens       Date:  2002-07       Impact factor: 4.844

10.  Cathepsin L colocalizes with chromogranin a in chromaffin vesicles to generate active peptides.

Authors:  Nilima Biswas; Juan L Rodriguez-Flores; Maite Courel; Jiaur R Gayen; Sucheta M Vaingankar; Manjula Mahata; Justin W Torpey; Laurent Taupenot; Daniel T O'Connor; Sushil K Mahata
Journal:  Endocrinology       Date:  2009-04-16       Impact factor: 4.736

View more
  27 in total

Review 1.  Catestatin: a multifunctional peptide from chromogranin A.

Authors:  Sushil K Mahata; Manjula Mahata; Maple M Fung; Daniel T O'Connor
Journal:  Regul Pept       Date:  2010-01-28

2.  Catestatin (chromogranin A(352-372)) and novel effects on mobilization of fat from adipose tissue through regulation of adrenergic and leptin signaling.

Authors:  Gautam K Bandyopadhyay; Christine U Vu; Stefano Gentile; Howon Lee; Nilima Biswas; Nai-Wen Chi; Daniel T O'Connor; Sushil K Mahata
Journal:  J Biol Chem       Date:  2012-04-25       Impact factor: 5.157

Review 3.  Chromogranin A and derived peptides in health and disease.

Authors:  Y Peng Loh; Yong Cheng; Sushil K Mahata; Angelo Corti; Bruno Tota
Journal:  J Mol Neurosci       Date:  2012-03-03       Impact factor: 3.444

4.  Catestatin Gly364Ser Variant Alters Systemic Blood Pressure and the Risk for Hypertension in Human Populations via Endothelial Nitric Oxide Pathway.

Authors:  Malapaka Kiranmayi; Venkat R Chirasani; Prasanna K R Allu; Lakshmi Subramanian; Elizabeth E Martelli; Bhavani S Sahu; Durairajpandian Vishnuprabu; Rathnakumar Kumaragurubaran; Saurabh Sharma; Dhanasekaran Bodhini; Madhulika Dixit; Arasambattu K Munirajan; Madhu Khullar; Venkatesan Radha; Viswanathan Mohan; Ajit S Mullasari; Sathyamangla V Naga Prasad; Sanjib Senapati; Nitish R Mahapatra
Journal:  Hypertension       Date:  2016-06-20       Impact factor: 10.190

Review 5.  Cardiomyokines from the heart.

Authors:  Ayano Chiba; Haruko Watanabe-Takano; Takahiro Miyazaki; Naoki Mochizuki
Journal:  Cell Mol Life Sci       Date:  2017-12-13       Impact factor: 9.261

6.  Proteomic analysis yields an unexpected trans-acting point in control of the human sympathochromaffin phenotype.

Authors:  Stéphane Chiron; Zhiyun Wei; Yuqing Chen; Kuixing Zhang; Gen Wen; Wolfgang H Fischer; Sushil K Mahata; Daniel T O'Connor
Journal:  Circ Cardiovasc Genet       Date:  2011-05-06

7.  Increased plasma level of catestatin might be associated with poor prognosis in hemodialysis patients.

Authors:  Huaibin Sun; Wanhua Xian; Lina Geng; Engang Li; Zhiguo Peng; Jun Tian
Journal:  Int Urol Nephrol       Date:  2017-02-04       Impact factor: 2.370

8.  Impact of Chromogranin A deficiency on catecholamine storage, catecholamine granule morphology and chromaffin cell energy metabolism in vivo.

Authors:  Teresa Pasqua; Sumana Mahata; Gautam K Bandyopadhyay; Angshuman Biswas; Guy A Perkins; Amiya P Sinha-Hikim; David S Goldstein; Lee E Eiden; Sushil K Mahata
Journal:  Cell Tissue Res       Date:  2015-11-16       Impact factor: 5.249

9.  Novel peptide isomer strategy for stable inhibition of catecholamine release: application to hypertension.

Authors:  Nilima Biswas; Jiaur Gayen; Manjula Mahata; Ying Su; Sushil K Mahata; Daniel T O'Connor
Journal:  Hypertension       Date:  2012-11-05       Impact factor: 10.190

10.  Catestatin reverses the hypertrophic effects of norepinephrine in H9c2 cardiac myoblasts by modulating the adrenergic signaling.

Authors:  Md Jahangir Alam; Richa Gupta; Nitish R Mahapatra; Shyamal K Goswami
Journal:  Mol Cell Biochem       Date:  2019-12-02       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.